CHINARES PHARMA (03320): China Resources Sanjiu Medical & Pharmaceutical's net profit in the first three quarters was approximately 2.899 billion yuan, a decrease of 10.65% year-on-year.
China Resources Pharmaceutical Group (03320) announces that the operational total revenue of CR 2035 for the first three quarters of 2025 is approximately 219.86 million...
CHINARES PHARMA (03320) announced the performance of China Resources Sanjiu Medical & Pharmaceutical in the first three quarters of 2025. The total operating income was approximately 21.986 billion yuan, an increase of 11.38% year-on-year; net profit was about 2.899 billion yuan, a decrease of 10.65% year-on-year.
Related Articles
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
